vsmcs Search Results


90
Innoprot Inc human brain vascular smooth muscle cells hbvsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Brain Vascular Smooth Muscle Cells Hbvsmcs, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vsmcs/Human+Brain+Vascular+Smooth+Muscle+Cells/pmc08444498-129-3-13
Average 90 stars, based on 1 article reviews
human brain vascular smooth muscle cells hbvsmcs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

86
Wolters Kluwer Health vsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Vsmcs, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vsmcs/vsmcs/10__1097_slash_fjc__0000000000000982-137-21-42
Average 86 stars, based on 1 article reviews
vsmcs - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

90
ScienCell human dermis vsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Dermis Vsmcs, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vsmcs/human+dermis+vsmcs/pmc04997992-44-0-8
Average 90 stars, based on 1 article reviews
human dermis vsmcs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Hamamatsu vsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Vsmcs, supplied by Hamamatsu, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vsmcs/vsmcs/pm19098300-33-8-26
Average 90 stars, based on 1 article reviews
vsmcs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Sasco Inc sd rat vsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Sd Rat Vsmcs, supplied by Sasco Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vsmcs/sasco+vsmcs/us07101852-198-14-14
Average 90 stars, based on 1 article reviews
sd rat vsmcs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
ScienCell vsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Vsmcs, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vsmcs/vsmcs/pmc06430810__41467_2019_9086_MOESM1_ESM-112-92-93
Average 90 stars, based on 1 article reviews
vsmcs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
BioWhittaker Molecular Applications human aortic vsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Aortic Vsmcs, supplied by BioWhittaker Molecular Applications, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vsmcs/human+aortic+vsmcs/pm15885676-49-0-16
Average 90 stars, based on 1 article reviews
human aortic vsmcs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
TCS Cellworks human vsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Human Vsmcs, supplied by TCS Cellworks, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vsmcs/human+vsmcs/10__5603_slash_fhc__a2021__0015-47-0-6
Average 90 stars, based on 1 article reviews
human vsmcs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Sasco Inc molecules secreted by restenosis-prone sasco vsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Molecules Secreted By Restenosis Prone Sasco Vsmcs, supplied by Sasco Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vsmcs/molecules+secreted+by+restenosis+prone+sasco+vsmcs/us07101852-220-18-22
Average 90 stars, based on 1 article reviews
molecules secreted by restenosis-prone sasco vsmcs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Kurabo industries primary human aortic vsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Primary Human Aortic Vsmcs, supplied by Kurabo industries, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vsmcs/primary+human+aortic+vsmcs/10__1074_slash_jbc__m000828200-68-3-10
Average 90 stars, based on 1 article reviews
primary human aortic vsmcs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Sasco Inc vsmcs
MFG-E8 expression in <t>HBVSMCs</t> after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001
Vsmcs, supplied by Sasco Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vsmcs/vsmcs/us07101852-159-25-5
Average 90 stars, based on 1 article reviews
vsmcs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
SLIT2 LTD aav infected with vsmcs
Slit2 overexpression regulated the migration and proliferation of <t>VSMCs.</t> <t>AAV-blank</t> and AAV-Slit2( +) were transfected into VSMCs, and migration was detected by Transwell and wound-healing assays. Proliferation was measured by CCK8 and BrdU assays. A Western blotting was used to detect the efficiency of Slit2 overexpression with AAV-Slit2 ( +) transfected into VSMCs (β-actin was used as an internal control, n = 3, *** P < 0.001 with Student’s t test). B – C The effect of Slit2 overexpression on VSMC migration by Transwell assays ( n = 5, *** P < 0.001 with Student’s t test). D – E Wound healing was used to test the migration velocity of VSMCs ( n = 5, *** P < 0.001 with Student’s t test). F – G The proliferation of VSMCs was detected by CCK8 or BrdU assays ( n = 5, *** P < 0.001, **** P < 0.0001 with Student’s t test)
Aav Infected With Vsmcs, supplied by SLIT2 LTD, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vsmcs/aav+infected+with+vsmcs/pmc10615989-91-6-9
Average 90 stars, based on 1 article reviews
aav infected with vsmcs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


MFG-E8 expression in HBVSMCs after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001

Journal: Acta Neuropathologica Communications

Article Title: MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy

doi: 10.1186/s40478-021-01257-9

Figure Lengend Snippet: MFG-E8 expression in HBVSMCs after treatment with Aβ40 peptides. a Representative immunocytochemistry image showing the expression of MFG-E8 (green) and SMA (red) in HBVSMCs. b Cell viability after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. c Representative western blot images and quantification of MFG-E8 protein levels after 2 and 5 days of treatment with 25 μM Aβ40 peptide and the toxic Aβ40-D peptide, n = 3–4/group. d Cell viability of HBVSMCs co-treated with 2 µg/ml rhMFG-E8 and 25 μM Aβ40-D for 5 days (n = 5/group). e Cell viability of HBVSMCs treated with 25 μM Aβ40-D for 48 h after transfection with MFG-E8- or NT-siRNA (n = 5/group). A non-targeting siRNA (siNT) was used as a control. Significant differences among groups are indicated as * p < 0.05, ** p < 0.01, **** p < 0.0001

Article Snippet: Primary cultures of human brain vascular smooth muscle cells (HBVSMCs) were obtained from Innoprot (Derio, Bizkaia, Spain).

Techniques: Expressing, Immunocytochemistry, Western Blot, Transfection

Slit2 overexpression regulated the migration and proliferation of VSMCs. AAV-blank and AAV-Slit2( +) were transfected into VSMCs, and migration was detected by Transwell and wound-healing assays. Proliferation was measured by CCK8 and BrdU assays. A Western blotting was used to detect the efficiency of Slit2 overexpression with AAV-Slit2 ( +) transfected into VSMCs (β-actin was used as an internal control, n = 3, *** P < 0.001 with Student’s t test). B – C The effect of Slit2 overexpression on VSMC migration by Transwell assays ( n = 5, *** P < 0.001 with Student’s t test). D – E Wound healing was used to test the migration velocity of VSMCs ( n = 5, *** P < 0.001 with Student’s t test). F – G The proliferation of VSMCs was detected by CCK8 or BrdU assays ( n = 5, *** P < 0.001, **** P < 0.0001 with Student’s t test)

Journal: Journal of Cardiovascular Translational Research

Article Title: Hif-1α/Slit2 Mediates Vascular Smooth Muscle Cell Phenotypic Changes in Restenosis of Bypass Grafts

doi: 10.1007/s12265-023-10384-8

Figure Lengend Snippet: Slit2 overexpression regulated the migration and proliferation of VSMCs. AAV-blank and AAV-Slit2( +) were transfected into VSMCs, and migration was detected by Transwell and wound-healing assays. Proliferation was measured by CCK8 and BrdU assays. A Western blotting was used to detect the efficiency of Slit2 overexpression with AAV-Slit2 ( +) transfected into VSMCs (β-actin was used as an internal control, n = 3, *** P < 0.001 with Student’s t test). B – C The effect of Slit2 overexpression on VSMC migration by Transwell assays ( n = 5, *** P < 0.001 with Student’s t test). D – E Wound healing was used to test the migration velocity of VSMCs ( n = 5, *** P < 0.001 with Student’s t test). F – G The proliferation of VSMCs was detected by CCK8 or BrdU assays ( n = 5, *** P < 0.001, **** P < 0.0001 with Student’s t test)

Article Snippet: Thus, we used AAV infected with VSMCs to overexpress Slit2 (the overexpression efficiency is shown in Fig. A) to determine whether Slit2 regulated the migration (tested by Transwell and wound-healing assays) and proliferation (tested by CCK8 and BrdU assays) of VSMCs.

Techniques: Over Expression, Migration, Transfection, Western Blot, Control

Slit2 knockdown regulated the migration and proliferation of VSMCs. Negative control (NC) and Slit2 siRNA were transfected into VSMCs, and migration was detected by Transwell and wound-healing assays. Proliferation was measured by CCK8 and BrdU assays. A Western blotting was used to detect the efficiency of Slit2 knockdown with Slit2 siRNA transfected into VSMCs (β-actin was used as an internal control, n = 3, ** P < 0.01 with Student’s t test). B – C The effect of Slit2 knockdown on VSMC migration by Transwell assays ( n = 5, **** P < 0.0001 with Student’s t test). D – E Wound healing was used to test the migration velocity of VSMCs ( n = 5, **** P < 0.0001 with Student’s t test). F – G The proliferation of VSMCs was detected by CCK8 or BrdU assays ( n = 5, *** P < 0.001, **** P < 0.0001 with Student’s t test)

Journal: Journal of Cardiovascular Translational Research

Article Title: Hif-1α/Slit2 Mediates Vascular Smooth Muscle Cell Phenotypic Changes in Restenosis of Bypass Grafts

doi: 10.1007/s12265-023-10384-8

Figure Lengend Snippet: Slit2 knockdown regulated the migration and proliferation of VSMCs. Negative control (NC) and Slit2 siRNA were transfected into VSMCs, and migration was detected by Transwell and wound-healing assays. Proliferation was measured by CCK8 and BrdU assays. A Western blotting was used to detect the efficiency of Slit2 knockdown with Slit2 siRNA transfected into VSMCs (β-actin was used as an internal control, n = 3, ** P < 0.01 with Student’s t test). B – C The effect of Slit2 knockdown on VSMC migration by Transwell assays ( n = 5, **** P < 0.0001 with Student’s t test). D – E Wound healing was used to test the migration velocity of VSMCs ( n = 5, **** P < 0.0001 with Student’s t test). F – G The proliferation of VSMCs was detected by CCK8 or BrdU assays ( n = 5, *** P < 0.001, **** P < 0.0001 with Student’s t test)

Article Snippet: Thus, we used AAV infected with VSMCs to overexpress Slit2 (the overexpression efficiency is shown in Fig. A) to determine whether Slit2 regulated the migration (tested by Transwell and wound-healing assays) and proliferation (tested by CCK8 and BrdU assays) of VSMCs.

Techniques: Knockdown, Migration, Negative Control, Transfection, Western Blot, Control

Hypoxia downregulated Slit2 expression via Hif-1α. A DAPI (blue), Slit2 (green), Hif-1α (red), and αSMA (pink) were labeled on the arteries of the VGR and non-VGR groups. B The fluorescence intensity of Slit2 and Hif-1α ( n = 5, *** P < 0.001, **** P < 0.0001 with Student’s t test). C The ratio of colocalization of Slit2 and Hif-1α in α-SMA ( n = 5, **** P < 0.0001 with Student’s t test). D and E VSMCs were incubated with hypoxia for 1, 3, 6, and 9 h, and the expression of Slit2 and Hif-1α was detected by western blotting. β-actin was used as an internal control ( n = 5, ** P < 0.01 with Dunnett’s multiple comparison test). F VSMCs were treated with agonist or inhibitor under normoxia or hypoxia, and the expression was tested by western blotting (β-actin was used as an internal control, n = 5, **** P < 0.0001 with one-way ANOVA)

Journal: Journal of Cardiovascular Translational Research

Article Title: Hif-1α/Slit2 Mediates Vascular Smooth Muscle Cell Phenotypic Changes in Restenosis of Bypass Grafts

doi: 10.1007/s12265-023-10384-8

Figure Lengend Snippet: Hypoxia downregulated Slit2 expression via Hif-1α. A DAPI (blue), Slit2 (green), Hif-1α (red), and αSMA (pink) were labeled on the arteries of the VGR and non-VGR groups. B The fluorescence intensity of Slit2 and Hif-1α ( n = 5, *** P < 0.001, **** P < 0.0001 with Student’s t test). C The ratio of colocalization of Slit2 and Hif-1α in α-SMA ( n = 5, **** P < 0.0001 with Student’s t test). D and E VSMCs were incubated with hypoxia for 1, 3, 6, and 9 h, and the expression of Slit2 and Hif-1α was detected by western blotting. β-actin was used as an internal control ( n = 5, ** P < 0.01 with Dunnett’s multiple comparison test). F VSMCs were treated with agonist or inhibitor under normoxia or hypoxia, and the expression was tested by western blotting (β-actin was used as an internal control, n = 5, **** P < 0.0001 with one-way ANOVA)

Article Snippet: Thus, we used AAV infected with VSMCs to overexpress Slit2 (the overexpression efficiency is shown in Fig. A) to determine whether Slit2 regulated the migration (tested by Transwell and wound-healing assays) and proliferation (tested by CCK8 and BrdU assays) of VSMCs.

Techniques: Expressing, Labeling, Fluorescence, Incubation, Western Blot, Control, Comparison

Overexpression of Slit2 delayed VGR and phenotypic switching of VSMCs in rats. AAV-blank and AAV-Slit2( +) were injected into the rats with abdominal aortic transplantation. The patency of aorta bypass grafts was observed by echocardiography, and phenotype switching of VSMCs was detected by western blotting. A Flowchart of the animal experiments. B and C The vascular diameter and PW velocity were measured ( n = 10, * P < 0.05, ** P < 0.01 with Student’s t test). D The number of different stenosis rates in the rats with abdominal aortic transplantation. E The Slit2, Hif-1α, contractile phenotype (αSMA and MYH11), and synthetic phenotype (OPN and MGP) were tested by western blots (β-actin was used as an internal control, n = 10, *** P < 0.001, **** P < 0.0001 with Student’s t test)

Journal: Journal of Cardiovascular Translational Research

Article Title: Hif-1α/Slit2 Mediates Vascular Smooth Muscle Cell Phenotypic Changes in Restenosis of Bypass Grafts

doi: 10.1007/s12265-023-10384-8

Figure Lengend Snippet: Overexpression of Slit2 delayed VGR and phenotypic switching of VSMCs in rats. AAV-blank and AAV-Slit2( +) were injected into the rats with abdominal aortic transplantation. The patency of aorta bypass grafts was observed by echocardiography, and phenotype switching of VSMCs was detected by western blotting. A Flowchart of the animal experiments. B and C The vascular diameter and PW velocity were measured ( n = 10, * P < 0.05, ** P < 0.01 with Student’s t test). D The number of different stenosis rates in the rats with abdominal aortic transplantation. E The Slit2, Hif-1α, contractile phenotype (αSMA and MYH11), and synthetic phenotype (OPN and MGP) were tested by western blots (β-actin was used as an internal control, n = 10, *** P < 0.001, **** P < 0.0001 with Student’s t test)

Article Snippet: Thus, we used AAV infected with VSMCs to overexpress Slit2 (the overexpression efficiency is shown in Fig. A) to determine whether Slit2 regulated the migration (tested by Transwell and wound-healing assays) and proliferation (tested by CCK8 and BrdU assays) of VSMCs.

Techniques: Over Expression, Injection, Transplantation Assay, Western Blot, Control